Treatment of Non-Severe COVID-19 Outpatients With Xagrotin, Phase 3
Status:
Not yet recruiting
Trial end date:
2022-07-07
Target enrollment:
Participant gender:
Summary
This is an interventional, multi-center, randomized study. Adults with confirmed covid-19
disease not more than 10 days before enrollment date will be recruited (n=1000). Patients in
same condition who get treated with standard of care will be randomly assigned to the control
group (n=1000), and patients in same condition who get treated with standard of care will be
randomly assigned to the placebo group (n=1000). The investigators analyze the effect of
Xagrotin, and also investigate impact of different characteristics for instance gender, age,
duration of disease, smoking habits and concomitant diseases on the outcome.